Meningiomas are the most common primary intracranial tumors,1 and are mostly treated with surgery and ionizing radiation.2 A subgroup of meningiomas recur despite multimodal therapy, and medical treatments are actively being investigated for meningiomas that are resistant to standard interventions.3 Immune checkpoint inhibitors (ICI) that target interactions between programmed death receptor (PD-1) and programmed death ligand 1 (PD-L1) have revolutionized the treatment of solid tumors.4 The efficacy of ICI in meningiomas is under investigation.5,6. Here, CD274 is linked to meningioma.